AbbVie Beats Q1 Earnings Despite IPR&D Headwinds, Raises Full-Year Guidance

AbbVie delivered stronger-than-expected first-quarter 2026 results, with adjusted earnings per share of $2.65 representing a 7.7% increase year-over-year despite absorbing a significant $0.41 per share impact from acquired intellectual property and milestone expenses. The pharmaceutical giant raised its full-year guidance on the back of robust growth from its immunology franchise.

Key Numbers

The numbers tell a story of successful portfolio transition. Total revenue reached $15.002 billion in the first quarter, climbing 12.4% on a reported basis (10.3% operationally), handily exceeding Wall Street expectations. Adjusted earnings per share of $2.65 beat consensus estimates even after factoring in the hefty IPR&D charge, while GAAP EPS fell 45.8% to $0.39 due to these one-time expenses.

The immunology portfolio emerged as the clear growth engine, generating $7.29 billion in revenue, up 16.4% year-over-year. Within this segment, Skyrizi delivered blockbuster performance with $4.483 billion in sales (+30.9%), while Rinvoq contributed $2.119 billion (+23.3%). These gains more than offset Humira's expected decline to $688 million (-38.6%) as the former mega-blockbuster continues losing ground to biosimilar competition.

Neuroscience delivered the quarter's most impressive growth rate, with revenue surging 26% to $2.875 billion. Vraylar reached $905 million in sales (+18.4%), while Botox Therapeutic crossed the billion-dollar quarterly mark at $1.009 billion (+16.5%). The migraine franchise combining Ubrelvy and Qulipta generated $635 million, with both drugs posting growth rates exceeding 40%. Vyalev, AbbVie's newest Parkinson's treatment, contributed $201 million in its early commercial stages.

The oncology portfolio remained essentially flat at $1.631 billion (-0.2%), with Venclexta's 15.7% growth to $770 million offsetting Imbruvica's 24.7% decline to $556 million. Elahere, the company's ovarian cancer therapy, showed modest growth at $198 million (+10.7%).

Aesthetics revenue of $1.186 billion grew 7.6%, led by Botox Cosmetic's strong 20.2% increase to $668 million, while Juvederm remained flat at $232 million.

Operationally, AbbVie maintained healthy margins with an adjusted gross margin of 83.6% and an adjusted operating margin of 40.8%. The company's adjusted tax rate of 15.4% came in below the GAAP rate of 32.9%, contributing to bottom-line performance.

What Management Said

CEO Robert A. Michael struck an optimistic tone, emphasizing that first-quarter results "exceeded our expectations" and highlighting the company's "key growth drivers" as the foundation for raising full-year guidance. His commentary focused on AbbVie's dual strengths: current commercial execution and pipeline advancement.

"We are generating exciting data and advancing numerous programs across all stages of development," Michael stated, signaling confidence in the company's ability to sustain growth beyond its current portfolio. "Our pipeline progress and solid business fundamentals position AbbVie for robust long-term growth."

Management's decision to raise full-year 2026 adjusted EPS guidance to $14.08-$14.28 from the previous $13.96-$14.16 range, even after absorbing the $0.41 IPR&D impact, sends a clear signal about underlying business momentum. The company explicitly noted this guidance excludes any additional IPR&D charges that might occur after the first quarter, suggesting potential for further upside if deal-making remains modest.

The company also announced significant manufacturing investments totaling $1.78 billion, including a new 185-acre campus in Durham, North Carolina, and expanded facilities in Illinois. Management positioned these investments as supporting "next-generation" medicines across immunology, neuroscience, and the emerging obesity category, indicating confidence in long-term demand.

What to Watch

Several critical developments warrant investor attention in coming quarters. First, the Humira-to-Skyrizi/Rinvoq transition remains the portfolio's most important dynamic. With Skyrizi approaching an $18 billion annual run rate and Rinvoq exceeding $8 billion annualized, these drugs have successfully filled most of the Humira revenue gap. The key question becomes whether their growth rates can sustain at current levels as the base effects become more challenging.

Regulatory catalysts loom large on the horizon. AbbVie awaits FDA decisions on Skyrizi's subcutaneous induction for Crohn's disease and Rinvoq's expansion into alopecia areata, both potential label expansions that could drive incremental growth. The company's response to the Complete Response Letter for trenibotulinumtoxinE (trenibotE) will determine timing for this potentially differentiated aesthetics product.

The neuroscience portfolio's momentum deserves particular attention. With 26% growth driven by multiple products rather than a single blockbuster, this therapeutic area has emerged as a potential third pillar alongside immunology and oncology. Vyalev's early commercial trajectory and the continued expansion of the migraine franchise could provide upside surprises.

Perhaps most intriguing is ABBV-295, the company's non-incretin obesity candidate showing "clinically meaningful" weight reduction in Phase 1 trials. In a market dominated by GLP-1 agonists, a differentiated mechanism could position AbbVie to capture share in the rapidly expanding obesity market. Further clinical data expected later this year will be crucial in validating this opportunity.

The oncology portfolio's flat performance raises questions about growth sustainability. While Venclexta's new all-oral combination with acalabrutinib for CLL and Elahere's expanding ovarian cancer data are positive, the portfolio needs additional drivers to offset Imbruvica's ongoing decline.

Finally, the company's approach to business development bears watching. The $750 million in Q1 IPR&D charges suggests active deal-making, but management's conservative guidance approach (excluding future deals) provides a cushion for additional acquisitions without negative earnings surprises.

AbbVie has successfully navigated its most significant patent cliff challenge, with new growth drivers more than compensating for Humira's decline. The raised guidance, strong pipeline progress, and diversified growth across therapeutic areas position the company well for sustained performance, though investors should monitor the durability of current growth rates and the progression of key pipeline assets.